Skip to main navigation Skip to search Skip to main content

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

  • CASPIAN investigators
  • Hospital Universitario 12 de Octubre
  • BHI of Omsk Region Clinical Oncology Dispensary
  • Cancer and Hematology Centers of Western Michigan
  • Asklepios Lung Clinic
  • Okayama University
  • Odessa National Medical University
  • Omsk Regional Cancer Center
  • Krankenhaus Nord
  • Istanbul University - Cerrahpaşa
  • Samsung Changwon Hospital
  • Kyiv City Clinical Oncological Centre
  • Russian Ministry of Health
  • AO Ospedali Riuniti PO Vincenzo Cervello
  • Charles University
  • Zaporizhia Medical Academy of Post-Gradate Education Ministry of Health of Ukraine
  • Tuberculosis and Lung Disease Hospital
  • Semmelweis University
  • University Hospital St. Marina
  • AstraZeneca
  • University of California at Los Angeles

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science